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Targeting neonatal ischemic brain injury with a
pentapeptide-based irreversible caspase inhibitor
D Chauvier1,2, S Renolleau3,4,5, S Holifanjaniaina6,7, S Ankri1,2, M Bezault1,2, L Schwendimann6,7, C Rousset8,9, R Casimir1,2,10,
J Hoebeke10, M Smirnova1,2, G Debret11,12, A-P Trichet2, Y Carlsson9,13, X Wang9, E Bernard2, M He´bert2, J-M Rauzier14,15,
S Matecki16,17, A Lacampagne15,17, P Rustin6,7, J Mariani3,4,18, H Hagberg8,9,13, P Gressens6,7,8, C Charriaut-Marlangue3,4
and E Jacotot*,1,2,6,7,8
Brain protection of the newborn remains a challenging priority and represents a totally unmet medical need. Pharmacological
inhibition of caspases appears as a promising strategy for neuroprotection. In a translational perspective, we have developed a
pentapeptide-based group II caspase inhibitor, TRP601/ORPHA133563, which reaches the brain, and inhibits caspases
activation, mitochondrial release of cytochrome c, and apoptosis in vivo. Single administration of TRP601 protects newborn
rodent brain against excitotoxicity, hypoxia–ischemia, and perinatal arterial stroke with a 6-h therapeutic time window, and has
no adverse effects on physiological parameters. Safety pharmacology investigations, and toxicology studies in rodent and
canine neonates, suggest that TRP601 is a lead compound for further drug development to treat ischemic brain damage in
human newborns.
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Worldwide estimations indicate more than 2 million non-
infectious neonatal deaths per year.1 Neonatal ischemic brain
injuries, such as stroke (focal cerebral ischemia involving middle
cerebral artery occlusion (MCAO)) or hypoxia–ischemia (HI)
(involving systemic asphyxia), are major and untreated causes
of newborn morbidity and mortality.2,3 Of the infants who survive
the first few hours after intrapartum-related neonatal deaths
(previously called ‘birth asphyxia’), as many as an annual
1 million may develop cerebral palsy, learning difficulties or other
disabilities.4 Recent clinical trials show that therapeutic inter-
vention by brain cooling beginning up to 6 h after perinatal
asphyxia reduces cerebral injury and improves outcomes in term
infants.5 Although these studies provide proof of concept that in
this context cell death is both delayed and preventable, the
protection is limited and there is still no treatment available for
perinatal stroke or brain injury occurring in preterm infants.6
Ischemic brain injury in the developing brain involves
several factors such as excitotoxicity, oxidative stress, and
inflammation, which accelerate cell death through either
apoptosis or necrosis, depending on the region of the brain
affected and on the severity of the insult.7,8 Accumulating data
suggest that apoptotic mechanisms have a more prominent
role in the evolution of ischemic brain injury in neonatal
rodents9–11 and humans12 than in adult brain ischemia,13,14
and that apoptosis involves the mitochondrial release of
cytochrome c11 and apoptosis-inducing factor (AIF),11,15,16
which activate caspase-dependent10,16 and -independent
execution pathways,13,16 respectively.
Caspases are a class of cysteine endoproteases that have
strict specificity for an aspartic residue at the S1 subsite.17,18
Some caspases are important mediators of inflammation and
others are involved in the apoptosis of mammalian cells,
where they participate in signaling and effector pathways.19
On the basis of the optimal four-amino-acid sequence to the
left of the cleavage site, caspases may be classified into three
groups: group I contains caspase-1, -4, and -5 (optimal
tetrapeptide: WEHD), group II contains caspase-2 (Casp2), -3
(Casp3), and -7 (Casp7) (optimal tetrapeptide: D[E/A]XD),
and group III contains caspase-6, -8 (Casp8), -9 (Casp9), and
-10 (optimal tetrapeptide: [V/L]EXD).20–22
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Both pancaspase inhibition and Casp3-selective inhibition
have been reported to be neuroprotective in various rodent
models of neonatal brain injury,13,23,24 opening the possibility
for pharmacological intervention.6 However, lack of protection
with caspase inhibitors was also reported,25,26 possibly
reflecting differences between experimental models or set-
tings (e.g., the age of animals26), specific in vivo properties of
the used inhibitors (e.g., brain penetration27), and/or a shift to
caspase-independent cell death pathways (e.g., AIF, auto-
phagic death, necroptosis).
The role of individual caspases in the developing brain is not
fully understood. Genetic analysis using constitutive defi-
ciency revealed that Casp3 and Casp9 execute programmed
(physiological) cell death in the central nervous system,28,29
whereas Casp2 does not.30 Aggravation of HI-induced lesions
was reported in Casp3-null mice.31 In contrast, genetic
inhibition of Casp2 is neuroprotective in newborn mice
exposed to HI or excitotoxic challenges.32
In a translational attempt to generate an efficient and safe
Casp2/group-II caspase inhibitor, we have developed a potent
pentapeptide-based irreversible caspase inhibitor. We report
here the preclinical evaluation of this compound and present
data supporting a potent neuroprotective role against perina-
tal ischemic brain damage in a variety of in vivo models,
potentially opening an avenue for treatment.
Results
Design of a caspase inhibitor adapted for neuroprotection
in neonates. We previously showed that the pancaspase
inhibitor quinolyl-carbonyl-Val-Asp-difluorophenoxymethyl-
ketone (Q-VD-OPh) has enhanced in vitro and in vivo
pharmacological properties,33 together with potent neuro-
protective effects in neonatal brain injury experimental
models.10,16,34 We reasoned that an in vivo efficient group
II-selective caspase inhibitor might combine an amino-terminal
quinolyl-carbonyl and a C-terminal fluorophenoxymethyl
ketone warhead (CH2OC6H3-F2) with the Casp2-preferred
pentapeptide backbone VDVAD,20,33,35,36 a sequence that is
also efficient as a substrate for Casp3,37 but is a weaker
substrate for group-I and -III caspases (data not shown and
McStay et al.37). Using the reported Casp2 crystallographic
data,38 we modeled pentapeptide structures within the
Casp2 active site (Figure 1a and Supplementary Figure
S1), and chose to add methyl ester group to the lateral chain
of each Asp residues to enhance lipophilicity (a well-known
approach to promote blood–brain barrier penetration) and
delay degradation by proteases in vivo. The resulting
substituted pentapeptide quinolin-2-carbonyl-VD(OMe)VAD
(OMe)-CH2-O(2,6F2)Ph (referred thereafter as TRP601) was
selected (Figure 1b). TRP601 is an irreversible caspase
inhibitor that, similar to other VDVAD-based inhibitors,20,21,37
is a potent inhibitor of group II caspases. Indeed, in vitro
kinetic analysis showed that TRP601 potently inhibits Casp3
(IC50/Casp3/TRP601¼ 47.3±11.2 nM; k3/Ki¼ 36 025/M/s; n¼ 3)
and also inhibits recombinant Casp2 (IC50/Casp2/TRP601¼
479.8±79.3 nM; k3/Ki¼ 1243/M/s; n¼ 3) (Figures 1c and d).
According to its irreversible nature, TRP601 showed
a fourfold IC50 reduction if preincubated 45 min with
Casp2 before substrate addition (IC50/rCasp2/TRP601/45 min¼
127±25 nM; n¼ 3).
As expected, TRP601 had no substantial activity outside
the caspase family, as found in a binding screen of 110
different receptors, transporters and ion channels, and 56
enzyme activity assays, including calpains, various cathe-
psins (B, H, G, L), granzyme B, and several glutamatergic
sites such as N-methyl-D-aspartatic acid and a-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (Table 1). When
used in cell culture assays like serum-deprived primary
embryonic cortical neurons,39 TRP601 prevented caspase
activation and cell death (Figure 1e). Following intravenous
(i.v.) administration in adult rats, TRP601 quickly entered the
brain (Figure 1f; Tmax¼ 25 min in the brain; Cmax¼ 120 ng/ml
in the brain, 1 mg/kg, i.v. bolus dose). Interestingly, an active
metabolite D2Me-TRP601 (TRP601 devoid of methyl ester
Figure 1 Design and pharmacological evaluation of TRP601. (a) Substrate binding region of caspase-2 (Casp2) in complex with TRP601. The quinolin-2-carbonyl-Val-
Asp(OMe)-Val-Ala-Asp(OMe)-CH2- moiety is shown in sticks representation with the atoms represented as follows: gray¼ carbon; white¼ hydrogen; blue¼ nitrogen; and
red¼ oxygen. The S–C covalent bond between the Cys-155 residue and the C terminus CH2 of TRP601 is represented in yellow. The electric interactions (hydrogen bonds
and salts bridges) are represented by the dashed, green lines. The enzyme residues that interact with the inhibitor are shown by the wireframe representation. Right panel: the
table shows the minimal energy (kcal/mol, Emin) of the Casp2–TRP601 complex resulting from electric or Coulombic component (Ec) together with repulsion–attraction
component (Evw). The interaction energy of the Casp2–TRP601 complex is 147.28 kcal/mol. Owing to the C–S covalent bond, the Asp residue in P1 contributes to about
30% of the interaction energy. The Asp in P4 and the Val in P5 have important non-covalent contributions to stabilization of the complex, 21% and 17%, respectively. Each of
the other two residues (Ala in P2 and Val in P3) contributes to about 12% of the interaction energy. (b) Structure of TRP601. (c) Representative dose–response curve of
human recombinant Casp2 and Casp3 inhibition by TRP601. Initial velocities were determined from standard colorimetric microplate assays. (d) Kinetic off rate (k3/Ki)
parameters of irreversible caspase inhibitors on Casp2 and Casp3. (e) TRP601 inhibits neuronal caspase activities and prevents serum deprivation (SD)-induced cell death.
High-density E14 cortical neuron cultures were subjected to 24 h SD in the presence or absence of 50 mM TRP601. Histograms indicate the means (±S.D.) of 15 independent
experiments. (f) Representative pharmacokinetic of TRP601 after intravenous (i.v.) administration in adult rats, through liquid chromatography-mass spectrometry (LC-MS/
MS) detection in the plasma and brain homogenates. Note that following intraperitoneal (i.p.) administration of the same dose, TRP601 was detected in the brain at 0.25 h
(brain Cmax¼ 25 ng/ml) and the Cmax (20 ng/ml) was obtained in the plasma according to a plateau between 0.5 and 2 h. (g–j) TRP601 reduces excitotoxic lesions in neonates.
The 5-day-old mice were subjected to intracerebral ibotenate injection and killed at different time points (g¼ 5 days; h and i¼ 24 h; j¼ 8 h) following the excitotoxic challenge
to determine the impact of TRP601, TRP801, and TRP901 (1 mg/kg; i.p.) on lesion severity (g), microgliosis (h), astrogliosis (i), and group II caspases activity (j). Histograms
show mean lesion volume (g;’, vehicle, n¼ 16; TRP601, n¼ 16; TRP801, n¼ 7; TRP901, n¼ 8), cell density (h and i; n¼ 10 per group), or VDVADase activity (j; n¼ 5
per group)±S.E.M. Asterisks indicate differences from control (’) (*Po0.05, **Po0.01, ***Po0.001 in Kruskal–Wallis post hoc Dunn’s for g, Mann–Whitney for h–j).
(k) TRP601 does not enhance protection conferred by short interfering RNA (siRNA)-mediated genetic inhibition of Casp2. The 5-day-old mice were subjected to intracerebral
injection (as in c) of either an siRNA against Casp2 (si2-a) or a control siRNA (si2Co), as indicated. After 24 h, ibotenate was administered (intracerebroventrally (i.c.v.)),
followed immediately by vehicle (&, n¼ 20;’, n¼ 20) or TRP601 (’; n¼ 24) administration (i.p.). See Supplementary Table 1 for exact values and detailed statistical
analysis
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groups on Asp lateral chains) was progressively generated in
the blood. We have re-synthesized this metabolite and found
that it strongly inhibits Casp3 (IC50/Casp3/D2Me-TRP601 against
recombinant Casp3 (rCasp3)¼ 0.42±0.16 nM; k3/Ki¼
34 782 163/M/s) and Casp2 (IC50/Casp2/D2Me-TRP601 against
rCasp2¼ 7.4±3.1 nM; k3/Ki¼ 182 801/M/s; n¼ 3) in vitro.
Table 1 Comprehensive in vitro pharmacology profile of TRP601
Non-peptide receptors Peptide receptors Nuclear receptors
Adenosine Angiotensin-II Glucocorticoid
Adrenergic Bombesin Estrogen alpha
Cannabinoid Calcitonin gene-related peptide Androgen
Dopamine Chemokine
GABA Cholecystokinin Ion channels
Glutamate Complement 5a Ca2+ channels
Glycine Endothelin K+ channels
Histamine Galanin Na+ channel
Imidazole Glucagon
Leukotriene Growth hormone secretagogue Enzymes
Melatonin Melanin-concentrating hormone Kinases
Muscarinic Motilin Phosphatases
Nicotinic Neurokinin Serine proteases
Purinergic Neuropeptide Y Cysteine proteases
Serotonin Neurotensin Aspartate proteases
Sigma Opioid and opioid-like Arachidonic acid metabolism
Somatostatin Prostaglandin metabolism
Amine transporters Thyroid hormone Monoamine synthesis and metabolism
Choline Urotensin-II Neurotransmitter synthesis and metab.
Dopamine Vasoactive intestinal peptide Nitric oxide synthesis
GABA Rolipram Second messenger systems
Norepinephrine Vasopressin ATPases
Seretonin Lipid synthesis
Metalloproteases
Miscellaneous enzymes
TRP601 (10mM) did not significantly modify the activity of 56 enzymes and did not impair or increase the binding of specific ligands to their receptors (110 receptors,
channels, or transporters tested). Synthetic list of enzymes, peptide and non-peptide receptors, nuclear receptors, ion channels, or amine transporters, challenged
with TRP601 (see details in Supplementary Table S3)
Figure 2 TRP601 has neuroprotective effects in a perinatal stroke model. The 7-day-old rats underwent electrocoagulation of the left middle cerebral artery and transient
homolateral common carotid artery occlusion for 50 min, followed by 48 h of recovery. (a) Pre-treatment with TRP601 confers strong cerebroprotection. Vehicle (’; n¼ 15),
100mg TRP601 (&; n¼ 24) or 100mg TRP901 (’; n¼ 9) was injected intraperitoneally (i.p.) before ischemia. Histograms represent mean±S.E.M. Kruskal–Wallis
(P¼ 0.0004), post hoc Dunn’s (Po0.001 for TRP601 versus vehicle). (b) Dose–response of TRP601 administered 1 h after MCAO onset (n¼ 103, Po0.002 Kruskal–
Wallis). Histograms represent mean±S.E.M. Asterisks indicate the level of significance in Dunn’s post hoc. (c) Representative cresyl violet-stained coronal sections from
vehicle-treated and TRP601-treated (1 mg/kg i.p.; 1 h post-ischemia) animals at 48 h post-reperfusion at the level of dorsal hippocampus and anterior commissure. Dotted
lines indicate infarct area. Scale bar¼ 500 mm. (d) Time window for treatment with TRP601 (n¼ 274, Po0.0001 Kruskal–Wallis). Individual percentage infarct volumes at
48 h post-ischemia are shown in vehicle- (n¼ 43) or TRP601-treated rats (1 mg/kg; i.p.) at 1 h (n¼ 51, ***), 2 h (n¼ 45, ***), 3 h (n¼ 40, ***), 4 h (n¼ 48, *), and 6 h (n¼ 47, *)
post-occlusion (asterisks indicate the level of significance in Dunn’s post hoc). Temperature and body weight were systematically monitored in ischemic animals (treated or not
with TRP601) and were found unchanged during ischemia, at reperfusion, and up to 48 h post-ischemia. (e and f) TRP601 effects after intravenous injection. TRP601 was
administered intrajugularly 1 h after the ischemic onset (n¼ 15). (e) Representative micrographs of entire pup brains at 48 h post-stroke. Arrows indicate electrocoagulation
points. Upper micrograph shows representative lesion at 48 h with visible ischemic territory. Lower micrograph is representative for low lesional score found in 33% of animals
injected with 0.1 mg/kg TRP601. (f) Raustro-caudal profiles (coronal sections of ipsilateral hemisphere) after intravenous (i.v.) administration of TRP601 (1 h after ischemia) at
0.1 mg/kg (n¼ 15) or 1 mg/kg (n¼ 16). (g and h) TRP601 has long-term protective effects. Vehicle or 0.1 mg/kg TRP601 was i.p. injected 1 h after the ischemic onset. After
21 days of recovery, animals were killed. (g) Cresyl violet-stained coronal sections showing brain injury in a representative animal for each treatment (upper: bregma 0.7;
lower: 3.3 mm). Note that TRP601 reduces the cortical cavity and tissue loss in external and internal capsule (ec, ic), caudate putamen (CPu), and amygdaloid nucleus
(bregma 3.6, 4 mm; data not shown). (h) Quantification of the cavity volume (% cavitation) and hemispheric tissue loss (100% ipsi/contra) in the presence (n¼ 12) or
absence (n¼ 6) of TRP601. Data are mean±S.E.M. (bars) values. *P¼ 0.0017; #P¼ 0.0192 (Mann–Whitney). (i and j) In vivo and ex vivo cell death, at 48 h post-stroke, in
the ipsilateral cortex of vehicle- and TRP601-treated ischemic animals. Propidium iodide was injected intrajugularly (10 mg/kg) into rat pups before ischemia and coronal
sections were analyzed by fluorescence microscopy (i, representative micrograph; j, left histograms). Alternatively, coronal sections were subjected to in situ 30-OH end DNA
labeling (terminal deoxynucleotidyl transferase dUTP nick-end labeling , TUNEL), counterstained with Hoechst 33342, and analyzed by fluorescence microscopy (j). Data are
mean±S.E.M. (bars) values (n¼ 5). **P¼ 0.0079 (Mann–Whitney). The arrows point to apoptotic nuclei. Scale bar¼ 100mm. (k) Representative western blot analysis of
caspase-2 (Casp2) processing at 24 h post-ischemia in the presence or absence of TRP601 or TRP901 injected (1 mg/kg, i.p.) at reperfusion. Ipsilateral penumbra zone (IL)
and contralateral counterpart (CL) of hemispheres were dissected and homogenized before biochemical analysis. Co., control brains (without ischemia). (l) Detection of
caspase-like activities at 24 h post-stroke in ipsilateral penumbra zones. Histograms show means of VDVADase, DEVDase, and LEHDase activities of animals i.p.-treated (’,
n¼ 5) or not (&, n¼ 5) with TRP601 or TRP901. Note that kinetic analysis showed that the earliest and quantitatively major detected caspase-like activity is a VDVADase
activity that reached 14 pmol/min/mg at t¼ 5 h post-ischemia, whereas neither DEVDase nor LEHDase activities were detected (Supplementary Figure S5). (m) TRP601
prevents cytochrome c release in vivo. A representative western blot analysis is shown. MF: mitochondrial fraction; CF: cytosolic fraction (CF). (n) Electron microscopy analysis
of the mitochondria isolated from ischemic brains. The mitochondria isolated from vehicle-treated ipsilateral (IL), contralateral (CL) hemispheres, or TRP601-treated ipsilateral
(ILþ TRP601) hemispheres are shown. Each panel show an example of the dominant phenotype (460%) of the isolated mitochondria population
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TRP601 is neuroprotective in neonatal excitotoxic brain
injury. We next evaluated the effect of TRP601 after
excitotoxic neonatal brain injury. In 5-day-old mice
intracerebrally injected with ibotenate, a single
administration of TRP601 (intraperitoneal (i.p.); 1 mg/kg)
significantly reduced lesion volumes of cortical
(40.96±0.02%; Po0.001 Kruskal–Wallis post hoc
Dunn’s) (V¼ 0.23±0.07mm3, n¼ 16 versus controls
V¼ 0.37±0.06mm3, n¼ 16) and white matter (48.87±0.01%
reduction; Po0.01) (V¼ 0.11±0.03mm3, n¼ 16 versus
controls V¼ 0.18±0.08 mm3, n¼ 16) regions (Figure 1g). In
contrast, TRP901 (a DEVD-based preferential Casp3/Casp7
inhibitor) and TRP801 (a preferential Casp8 inhibitor40),
both designed with the same chemistry as TRP601
(Supplementary Figure S2), did not confer brain protection
against ibotenate challenge (Figure 1g). In these
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experimental conditions, TRP601 also reduced macrophage
activation (43.51±4.16% reduction; Po0.0001 Mann–
Whitney) and astrogliosis (37.69±3.15% reduction;
Po0.0001 Mann–Whitney) as demonstrated by histological
evaluation of lectine- (Figure 1h) and glial fibrillary acidic
protein -positive (Figure 1i) cell densities, respectively. In
addition, TRP601 strongly reduced the VDVADase-specific
activity (73% reduction; P¼ 0.0079 Mann–Whitney) when
studied 8 h after ibotenate treatment (Figure 1j).
Having found recently that genetic inhibition of caspase-2
(Casp2) protects newborn mice from ischemic brain injury,32
we further investigated the protective effect of TRP601 during
Casp2 silencing. When TRP601 was administered in mice
neonates treated with Casp2-specific siRNA, no significant
additional protection was found against ibotenate, neither in
the white matter nor in the cortical plate (Figure 1k and
Supplementary Table S1). This suggests that, at least in this
experimental setting, TRP601-mediated neuroprotection is
Casp2 dependent.
TRP601 is neuroprotective in neonatal rats after
ischemic stroke. We then investigated whether TRP601
might be operative in perinatal arterial stroke. The 7-day-old
rat pups were subjected to a permanent occlusion of the
MCAO and subsequent transient unilateral carotid ligation,41
a model of neonatal ischemia with reperfusion that induces
ipsilateral cortical injury associated with initiator and effector
caspase processing,42 extensive neuronal loss, inflammatory
responses, nitric oxide production and the evolution of a
cortical cavitary infarct.41
A single dose of TRP601 (5 mg/kg; i.p.) administered before
occlusion induces a highly significant reduction (59%) of
infarction (8.83±1.8%; n¼ 24) compared with the control
(21.67±1.65%; n¼ 15) (Figure 2a). In contrast, the Casp3/
Casp7 inhibitor TRP901 does not confer significant protection
(22.2±5.67%; n¼ 9). TRP601 also produces significant
reductions in cortical infarction when administered i.p. 1 h
after the ischemic onset (i.e., at reperfusion) at doses between
1mg/kg and 10 mg/kg (n¼ 103; Po0.002 Kruskal–Wallis),
with an optimal dose of 1 mg/kg (% infarction: 9.73±1.9%;
n¼ 18, Po0.001 post hoc Dunn’s; Figures 2b and c).
To determine the therapeutic time window of TRP601 in this
perinatal stroke rat model, we designed a large protocol
(n¼ 274 rat pups, two independent experimenters) with
randomized litters in each group (Po0.0001 Kruskal–Wallis;
Figure 2d). When injected 2 h post-ischemia at 1 mg/kg (i.p.),
TRP601-induced reduction of infarction was around 40%
(% infarction: 11.78±1.01%; n¼ 47,Po0.001 post hocDunn’s;
Figure 2d) and remained significant (19.18% reduction) when
TRP601 was added up to 6 h post-ischemia (% infarction:
16.01±0.92%; n¼ 47, Po0.05 post hoc Dunn’s; Figure 2d).
The most clinically relevant administration route being i.v.
injection, we set up similar experiments with post-ischemia
intrajugular bolus of TRP601. Lesion scores on the entire
brain and also section-based infarction quantifications con-
verged to conclude that i.v. injected TRP601 (0.1–1 mg/kg; 1 h
post-ischemia) considerably reduces ischemia-induced brain
lesions along the rostro-caudal axis (Figures 2e and f),
correlating with a significant neurological score amelioration in
sensory and motor profiling assays (Table 2). We further
investigated if cerebroprotection was long-lasting. At 21 days
post-ischemia, the ipsilateral hemisphere of vehicle-treated
animals exhibited a large cavity in the full thickness of the
frontoparietal cortex (% cavitation: 12.5±3.53%; n¼ 6) and a
tissue loss (32.33±5.56%), which were markedly reduced in
TRP601-treated rats (% cavitation: 1.42±0.68%; n¼ 12; %
tissue loss: 12.1±3.9%; Figures 2g and h), correlating with
reduced astrogliosis (Supplementary Figure S3). Hence, in
7-day-old rats subjected to perinatal stroke, TRP601 provided
sustained neuroprotection and neurological improvement,
with a 6 h time window for administration.
TRP601 prevents apoptosis, caspase activation and
cytochrome c release in vivo. Both in vivo propidium
iodide staining and ex vivo terminal transferase dUTP nick-
end labeling analysis of ipsilateral regions in brain sections
from ischemic pups revealed a massive TRP601-sensitive
cell death with apoptotic phenotype (Figures 2i and j). When
administered at reperfusion, TRP601 prevents Casp2
processing (Figure 2k) and activation of all caspase-like
activities, whereas TRP901 only reduces the DEVDase
activity (Figures 2k and l). Previous reports had suggested
that Casp2 may act directly and/or through Bid/Bax on
mitochondrial membranes.43,44 Using the mitochondria
isolated from neonatal brain, we found that a mixture
containing rCasp2 and full-length Bid induce TRP601-
sensitive cytochrome c release, correlating with Casp2-
induced Bid cleavage (Supplementary Figure S4). In
addition, cytochrome c detection at 24 h post-ischemia in
the ipsilateral cytosolic versus mitochondrial brain fraction
indicates that TRP601 (added at reperfusion; i.p.) prevents
the mitochondrial release of cytochrome c in vivo
(Figure 2m), correlating with TRP601-mediated prevention
of matrix swelling (Figure 2n).
TRP601 reduces HI brain injury. We next decided to
determine whether the TRP601 pharmacological spectrum of
use might include the most widely used neonatal HI model,
where a focal brain injury occurs in 8-day-old rats after
unilateral carotid ligation and exposure to 7.8 % oxygen for
50 min.45 Indeed, a single dose of TRP601 (1 mg/kg; i.p.)
administered just after hypoxia induces a significant
reduction of infarct volume (30.3%; P¼ 0.0239 Student’s
t-test; V¼ 60.22±8.47 mm3, n¼ 24 versus control
V¼ 86.43±6.54 mm3, n¼ 19), percentage infarction
(48.48±3.13% versus 34.17±4.69%; P¼ 0.0287 Mann–
Whitney; Figure 3a), and tissue loss (27.5%; P¼ 0.0412
Mann–Whitney; V¼ 88.64±11.17 mm3 versus control
V¼ 122.29±6.84 mm3; Figures 3b–d). An early TRP601-
sensitive, but TRP901-insensitive, VDVADase activity
(12 pmol/min per mg) was detected as early as 1 h post-HI
in the cortex (Figure 3e). TRP601 also reduced various
aspects of HI-induced white matter injury, including
neurofilament degradation (NF68: 64.24±8.5% versus
controls 87.66±5.32%; P¼ 0.049 Mann–Whitney)
(Figure 3f), oligodendroglial loss (CNPase: 69.56±8.37%
versus controls 91.29±2.59%; P¼ 0.0307 Student’s t-test)
(Figure 3g) and hypomyelination (MBP: 87.66±8.8% versus
controls 91.03±2.6%; P¼ 0.041 Student’s t-test) (Figures 3h
and i).
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TRP601 does not modify physiological parameters. It is
established that physiological variables can influence the
outcomes of ischemic injury.46 Importantly, when injected in
rat pups, TRP601 (1 mg/kg) does not significantly alter
physiological parameters, including systemic acid–base
balance (arterial blood pH, partial tension of O2, partial
tension of CO2 and plasma [HCO3
]), body weight,
temperature, or heart rate (Table 3). Echography and
transcranial color-coded duplex Doppler sonography
showed that heart function and cerebral perfusion are
unchanged in TRP601-exposed neonates (Table 3). In
addition, telemetry experiments in vigil dogs indicated that
Table 2 Neurological benefit at 48 h: effect of TRP601 (i.v., 1 mg/kg, 1 h post-ischemia) on general behavioral profiles
Naı¨ve (n¼ 20) Isch.+vehicle (n¼20) Isch.+TRP601 (n¼ 20) P-values (v2) (n¼20)
Spontaneous activity 1.8±0.4 0.3±0.6 1.1±0.6 0.026106
Walking (circle versus straight) 0.3±0.4 1.6±0.6 0.8±0.6 1.092106
Reaction to pain 1.7±0.6 0.7±0.6 1.2±0.6 95.33 106
Paw withdrawal 1.6±0.6 0.3±0.6 1.2±0.6 0.261106
Mean lesion volume (mm3) 0 24.3±2.5 9.2±2.3 NA
Sensorimotor neurological deficits were assessed in a blinded manner in 7-day-old rat pups. Animals were subjected to ischemia–reperfusion (as in Figures 2d–f) and
treated with 1 mg/kg TRP601 (i.v., 1 h post-ischemia). At 48 h post-ischemia, pups were tested for the following neurological signs and reflexes: (i) spontaneous
activity (spontaneous postural signs such as right forelimb flexion and thorax twisting and exploration of the cage); (ii) walking (after ischemia pups walk in circle rather
than straight); (iii) reaction to pain (the pup escapes after the tail is pinched); (iv) paw withdrawal (pups withdraw paw from adhesive pad). Grading scale of
neurological examination for each test item was: 2 for normal; 1 for intermediate; and 0 for abnormal. A neurological score (mean±S.E.M.) was attributed for each test
in each experimental condition (d.o.f. stands for degree of freedom in the w2 statistical test). NA, not applicable
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Figure 3 TRP601 reduces neonatal hypoxia–ischemia-mediated brain damage. The 8-day-old rats were subjected to transient unilateral carotid ligation and exposure to
7.8% oxygen during 50 min according to the Rice–Vannucci protocol. Pups were injected intraperitoneally (i.p.) with vehicle (’, n¼ 19) or 1 mg/kg TRP601 (&, n¼ 24)
immediately after the end of hypoxia. Bars indicate S.E.M. *Po0.05. (a and b) Histograms show % infarction (a) and mean volume tissue loss (b) measured at 72 h post-
hypoxia–ischemia (HI) after microtubule-associated protein 2 (MAP2) staining at each anatomical level. (c) Rostro-caudal profiles. (d) Representative micrograph for MAP2-
stained sections (bregma 3.14 mm). (e) Kinetics of Ac-VDVAD-AMC cleavage in the cortex from HI pups at 1, 8, or 24 h in the presence or absence of TRP601 (vehicle:
n¼ 7; TRP601: n¼ 8 for each time point; ***Po0.0001 two-way analysis of variance (ANOVA)). (f–i) Immunohistochemistry of subcortical white matter in vehicle- (’,
n¼ 19) and 1 mg/kg TRP601- (&, n¼ 24) treated pups. Histograms show: % NF68 loss (f), % CNPase loss (g), and % myelin basic protein (MBP) loss (h) measured at 72 h
post-HI. (i) Representative micrograph for MBP staining in the subcortical white matter. Cx, cortex; WM, white matter. Scale bar¼ 200mm
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vital signs, heart rate, and electrocardiogram profile including
QT interval corrected for heart rate were not affected by
TRP601 up to the maximal dose tested (i.e., 3 mg/kg, i.v.),
suggesting low potential for fatal tachyarrhythmia. Supra-
pharmacological doses of TRP601 in rats had no impact on
central nervous system functions, including behavior, spatial
activity, coordination, and memory.
To exclude the potential risk that TRP601 might affect the
physiological programmed cell death, which contributes to
normal brain maturation, TUNEL (terminal deoxynucleotidyl
transferase dUTP nick-end labeling) ex vivo studies were
performed, and it was found that rat pups treated with TRP601
at postnatal days 5 and 7 (after birth) showed no significant
changes in developmental cell death in the brain (Supple-
mentary Table S2). In addition, histological analysis in
7-day-old rat pups treated with high doses of TRP601 found
no influence on forebrain, middle brain, and hindbrain
maturation at 21 days of age (data not shown).
TRP601 safety profile in adult and neonates support
further translational steps. The bench to bedside
translation of any drug dedicated to the neonatal population
requires specific PK/PD considerations together with
combined toxicology evaluation in both adult and neonates.
For these reasons, having verified that TRP601 has no
hemolytic potency, no effect on bleeding time, no impact on
platelet aggregation, and low toxicities on various cultured
primary cells, we then investigated toxicology in adult
animals, together with dedicated studies in rodent and non-
rodent neonates (see Supplementary Materials and
Methods). In multiple-dose regulatory studies in adult dogs,
no TRP601-related cytotoxic effects were observed following
i.v. administration for 14 days at doses up to 3 mg/kg per day.
A good vascular and perivascular local tolerance was found
in rabbit ear. TRP601 was found not to be genotoxic when
evaluated in a battery of in vitro and in vivo assays, and
showed no antigenic response in rat. In 7-day-old rat pups,
single-dose administrations of TRP601 indicated low toxicity
of TRP601 (DL50i.v.¼ 60 mg/kg; DL30i.p.4200 mg/kg).
Studies with multiple-dose i.v. injections (once every 3 days
during a 2-week period, starting on postnatal day 1 in
newborn Beagle dogs) showed no adverse effect level at
15 mg/kg per injection once every 3 days.
Discussion
Neonatal ischemic brain injury triggers multiple pathways of
oxidant stress, inflammation, and excitotoxicity that lead to
massive cellular death in the ischemic territory. Caspase-
dependent programmed cell death importantly contributes to
this fate.7,9,10,14,15,23,24,32,42 In contrast to previous genera-
tions of aspartyl-fluoromethylketone (D-fmk)-based inhibitors
(e.g., z-VAD-fmk (N-benzyloxycarbonyl-Val-Ala-Asp(Ome)-
fluoromethylketone), boc-D-fmk (Boc-Asp (OMe)-fluoro-
methylketone)), aspartyl-methyloxyphenylketone-based inhibitors
(e.g., Q-VD-OPh) only target the caspase family, efficiently
inhibit (all) caspases, have low in vivo toxicity, and present
enhanced pharmacological properties.10,16,25,33 Our results
show that pharmacological inhibition of a subfamily of
caspases (Casp2, Casp3) with the pentapeptide-mOPh
derivative, TRP601, reduces cortical and white matter
damage in the neonatal brain after excitotoxicity, arterial
stroke, and HI. In all of these experimental paradigms,
TRP601 also reduces gliosis, an inflammatory response to
brain ischemia. It has been demonstrated recently that
caspase-8 and Casp3/7 are involved in regulating microglia
activation.47 Consequently, beside its direct protective effect
on neurons (as observed in primary cortical cell cultures), it
might be important to investigate whether TRP601 (or the
active metabolite D2Me-TRP601) could also exert cerebro-
protective effects through targeting the microglia.
Table 3 Physiological variables in TRP601-treated rat pups
Parameters Vehicle TRP601
Blood hemodynamics and biochemistry
Blood flow (n¼5, ml/min)
1 h 4.2±0.9 3.6±0.4
Resistance indexa (n¼8)
1 h (cerebral artery) 0.68±0.01 0.64±0.03
Bleeding time (n¼ 10)
1 h 319±34 395±103
Arterial pH (n¼8)
1h 7.42±0.03 7.42±0.02
PaO2 (n¼ 8, mm Hg)
1 h 70.84±6.38 69.82±2.24
PaCO2 (n¼ 8, mm Hg)
1 h 37.96±2.64 42.06±2.58
HCO3
 (n¼ 8, mM)
1 h 24.16±0.61 26.30±0.76
Cardiac physiology
Heart rate (n¼8, beat/min)
1 h 345±13 344±12
LVEDd (n¼ 8, mm)
1 h 0.293±0.015 0.310±0.015
LVO (n¼ 8, ml/min)
1 h 0.135±0.009 0.157±0.015
Fractional shortening (n¼8, %)
1h 54.39±0.96 49.97±2.11
VTIm (n¼8)
1 h 4.05±0.11 3.92±0.29
Core temperature (n¼10, 1C)
1 h 36.60±0.28 36.40±0.67
3 h 36.39±0.54 36.40±0.67
48 h 36.63±0.23 36.80±0.23
Body weight (n¼10, g)
Co. 19.49±1.43 19.18±0.95
1 h 19.35±1.72 20.40±1.67
48 h 20.96±1.25 20.90±0.67
14 days 69.56±1.60 62.00±2.50
Blood hemodynamics, biochemistry, cardiac physiology, temperature, and
body weight were evaluated before and 1 h after TRP601 (1 mg/kg) or vehicle
injection. Anterior cerebral arteries were located by transcranial color-coded
duplex sonography to measure peak systolic (Vs) and maximum end-diastolic
(Vd) velocities. Resistive index (RI) was calculated as follows: RI¼ ((VsVd)/
Vs), and corresponds to an index of cerebral perfusion. For cardiac physiology,
the left ventricle (LV) was imaged in short axis view, and diastolic diameter
(LVEDd) was defined as the largest LV area. The fractional shortening was
calculated with the following formula: FS (%)¼ ((LVEDdLVEDs)/
LVEDd) 100. LVED corresponds to left ventricular end-systolic diameter. A
pulsed-wave Doppler spectrum of aortic outflow was recorded from supras-
ternal view to evaluate left ventricular output (LVO). Velocity–time integral (VTI)
of aortic flow, aortic root diameter (CSA), and heart rate (HR) were measured to
calculate LVO as follows: LVO¼CSAVTIHR. A pulsed-wave Doppler
spectrum of mitral inflow (VTIm) was recorded from the apical four-chamber
view as an index of diastolic function. Statistical analysis was performed by a
mean comparison using a Scheffe test. aTranscranial Doppler sonography
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Our results indicate that TRP601 and its active metabo-
lite(s) (e.g., D2Me-TRP601) inhibit Casp3 and Casp2 in vitro
and in vivo. We also provide evidences suggesting that
TRP601 interrupts the mitochondrial (intrinsic) pathway of
apoptosis in the immature brain, possibly at the level of Casp-
2-mediated Bid cleavage, and upstream cytochrome c
release.39 We have recently reported that Casp2/ mice
subjected to neonatal HI presented significantly lower
cerebral infarction, reduced white matter injury, and reduced
Casp3 activation in the thalamus and hippocampus.32 Lesion
sizes and Casp3 activation were also found reduced in
Casp2-deficient newborn mice subjected to excitotoxicity.32 In
addition, we show here that combined administration of
TRP601 with Casp2 silencing did not show any additive effect
against ibotenate challenge. This suggests that the TRP601-
mediated neuroprotection is at least, in part, Casp2-dependent.
Taken together, our data suggest that the in vivo observed
neuroprotection and Casp3 inhibition by TRP601 are at least,
in part, Casp2-dependent. However, we could not formally
exclude that part of the neuroprotective effect of TRP601
could be related to a direct Casp3 inactivation by TRP601 or
D2Me-TRP601 (this latter being a very powerful Casp3
inhibitor in vitro). As the selective Casp3 inhibitor M826 was
previously found neuroprotective against neonatal HI,24 one
can suggest that the use of a group-II caspase inhibitor might
be of therapeutic interest to cover different conditions,
developmental stages, or regional mechanisms, where
Casp3/7 and Casp2 are variably expressed and activated
through different pathways.
Irrespective of these mechanistic considerations, TRP601
is a lead candidate for neuroprotective strategy in a variety of
perinatal brain injury conditions. The lack of detectable side
effects following in vivo administration of TRP601 to newborn
rodents and dogs support its further evaluation, possibly
in combination with hypothermia5 or other candidate treat-
ments.6,48
Materials and Methods
Animal models. Three different animal models were used: neonatal stroke,
excitotoxicity, and HI. Neonatal stroke (focal brain ischemia with reperfusion in the
7-day-old rat) was carried out according to Renolleau et al.10,41 For HI, 8-day-old
rats or alternatively 9-day-old mice were subjected to unilateral ligation of the left
carotid artery, followed by hypoxia (7.8% O2 for rats and 10% O2 for mice, 361C) for
50 min, as described.32 For drug-induced excitotoxicity, ibotenate was administered
i.c.v. to 5-day-old mice, as described.32 Details for each animal models are given in
Supplementary Material and Methods. SiRNAs were prepared as a solution in JetSI
according to the manufacturer’s recommendations (PolyPlus-transfection, Illkirch,
France). Final solution contained RNAse free water, 0.08 mM DOPE, 0.24%
chloroform/7% EtOH, glucose 12.5%, and 0.04 mM JetSI. For intracerebral siRNA
administration, 0.4mg siRNA/mice were administered (volume of injection¼ 2 ml)
24 h before ibotenate. SiRNA sequences and primers for PCR were reported
previously.32
Primary cortical neuron culture and cell death analysis. Primary
cortical neurons from E14 Swiss mice embryos (Janvier, Le Genest-St-Isle, France)
were cultured in N5 complete medium up to 6 DIV and subjected to serum
deprivation in the absence or presence of TRP601, or alternatively were transfected
with siRNAs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 24 h before
serum withdrawal. To monitor cell death parameters, neurons were
co-stained with Hoechst 33342 (nuclear condensation; Sigma, Saint Louis, MO,
USA), JC-1 (5,50,6,60-tetrachloro-1,10, 3,30-tetraethyl-benzimidazolylcarbocyanine
iodide) (mitochondrial transmembrane potential-sensitive probe), and 7-amino
actinomycin D (plasma membrane permeabilization; Sigma), and then subjected to
fluorescence microscopy (DM IRB; Leica, Rueil-Malmaison, France) and flow
cytometry (FACSCalibur; Becton Dickinson, San Jose, CA, USA) analysis, as
described previously.39 In cellula caspase activities were detected using FAM-
conjugated peptides (CaspaTag fluorescein Caspase Activity Kits; Q-Biogen, MP
Biomedicals, Illkirch, France), as described.39
Preparation and use of drug solutions. Synthesis of TRP601/
ORPHA133563 (also known as OPH016) is described in Supplementary
Materials and Methods). Research batches where synthesized in-house
(Dr. Richard Casimir). Additional batches were custom synthesized by MP
Biomedicals or alternatively by NeoMPs (PolyPeptide group, Strasbourg, France).
For regulatory safety studies, TRP601 process development and manufacturing of
GMP batches were subcontracted to NeoMPs (PolyPeptide group). For in vitro
studies TRP601 (C40H48F2N6O11; MW: 826.84), D2Me-TRP601 (C38H44F2N6O11;
MW: 798.79), TRP801 (MW: 771.76), and TRP901 (MW: 799.77) were initially
solubilized in 100% DMSO. The final concentration of DMSO wasr1%. For in vivo
efficacy experiments, TRP601, TRP801, and TRP901 were formulated in 0.9%
NaCl containing 10% DMSO for i.p. administration or 2.4% Tween 20 for i.v.
administration. I.v. administration of TRP601 to 7-day-old rats was carried out
intrajugularly using 27-gauge needles. All stock solutions and formulations were
verified using RP-HPLC. TRP601 has a high degree of lipophilicity (partition
coefficient, LogPoctanol/water¼ 3.89) and exhibits one pKa of 1.1 (assigned to the
quinoleine group), strongly suggesting that it remains neutral in the plasma.
Bioanalysis of TRP601 in fluids and organ homogenates was conducted by LC/MS/
MS analysis with a precision of 1.00 ng/ml in the plasma and 3.00 ng/g in
exsanguined brain homogenates (ADME Bioanalyses, Vergeze, France).
Molecular modeling. Starting from the crystal structure of the caspase-2-
inhibitor (Ac–LDESD–CHO) complex (1PYO), pentapeptide inhibitors (including
Ac–VDVAD–CHO and TRP601) were studied in an uncharged form and at a
dielectric constant of 1, using either Insight II or Discovery Studio 2.0 softwares
(Accelrys, San Diego, CA, USA). See details in Supplementary Materials and
Methods.
In vitro enzymatic assays. Kinetics were performed according to the
continuous method. Assays of chromogenic substrate cleavage contained in 100ml
caspase buffer (20 mM HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT, 2 mM EDTA),
117 ng of human active recombinant caspase-2 (Biomol, Plymouth, PA, USA) or
20 ng of human active recombinant caspase-3 (Sigma; no. C5974), and 100mM of
chromogenic substrate (Ac–DEVD–para-nitroaniline (pNA) for Casp3 and
Ac–VDVAD–pNA for Casp2) in the presence of a range of concentrations of
inhibitors. For Casp2 assays, the buffer was supplemented with 1 M succinate
(kosmotrope agent). Cleavage of the chromogenic substrate as a function of time
was monitored at 405 nm, and the initial velocity (V0) was determined from the linear
portion of the progress curve. The formation of pNA was followed every 30 s for
150 min at 371C with a microtiter plate reader (Paradigm Multi-Mode Microplate
Detection Platform, SoftMax Pro 5.2 software; Molecular Devices, St. Gre´goire
Ce´dex, France). V0, relative velocities, Km, and IC50 were determined from
experimental data using the GraphPad Prism 5.01 software program. Standard
deviations of the reported values were below 10%. Inhibitor binding affinity
(dissociation constant, Ki) and first-order rate constant (k3) parameters were
estimated using R (http://www.R-project.org) to fit the following equation from
Wu and Fritz49:
½Pt ¼ ½E0
½SK i
½IK s
 
ks
k3
 
1  ek3t= 1þðKi=½IÞð1þ½S=K sÞð Þ
h i
Other in vitro assays for calpains, cathepsins, and granzyme activities were
performed as described.33
Ex vivo biochemistry. Brains of rat or mice pups were removed just after
decapitation. Contralateral and ipsilateral hemispheres were frozen immediately
and kept at 801C. Alternatively, the ipsilateral hemisphere was rapidly micro-
dissected (at 41C) to mainly select the lesioned area (i.e., the estimated penumbra
zone for the neonatal stroke model). Brain samples processing and related
biochemical analyses are described in Supplementary Material and Methods.
Physiological parameters. Blood gas analyses and hemodynamic
evaluations conducted in newborn rats are described in Supplementary Materials
and Methods.
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Safety pharmacology and toxicology. Safety experiments conducted in
newborn dogs and rats are described in Supplementary Materials and Methods.
Statistics. Statistical analyses were conducted with Prism 4.0. Data are
presented as mean±S.E.M. and were first analyzed with a KS normality test. When
the data passed the normality test, the appropriate parametric test has been applied
(Student’s t-test or ANOVA), followed by the suitable post hoc test if necessary
(Bonferroni test). When the data did not pass the normality test, the appropriate non-
parametric test has been applied (Mann–Whitney or Kruskal–Wallis tests), followed
by the suitable post hoc test if necessary (Dunn’s test). Neurological scores were
statistically analyzed with a w2. Statistical significance is indicated by a single
asterisk (Po0.05), and two or three asterisks (Po0.01 oro0.001, respectively).
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